NCT06607458 2026-03-13
DEL-LIVER
Delcath Systems Inc.
Phase 2 Recruiting
Clinical Trials
17 trialsNCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT05083481 2026-02-27
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT06356311 2026-02-27
TroFuse-015
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05198934 2026-02-06
CodeBreak300
Amgen
Phase 3 Active not recruiting
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04626635 2026-02-02
COMBINE-EGFR-1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05405595 2026-01-07
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Adagene Inc
Phase 1/2 Recruiting
NCT07280377 2025-12-12
GOBLET
Oncolytics Biotech
Phase 1/2 Recruiting
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT05029882 2025-10-29
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
Phase 1 Active not recruiting
NCT05064059 2025-09-17
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06614192 2025-08-26
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Recruiting
NCT05328908 2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3 Terminated
NCT06199973 2025-07-17
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Active not recruiting
NCT04393298 2025-05-29
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Pharma
Phase 1/2 Completed
NCT05848739 2025-05-11
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Sapience Therapeutics
Phase 1 Recruiting